tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Myriad Genetics backs FY25 adjusted EPS view (2c)-2c, consensus 1c

Raises FY25 revenue view to $818M-$828M from $807M-$823M, consensus $811.08M. Raises FY25 adjusted EBITDA view to $27M-$33M from $19M-$27M. The company said, “Raised 2025 revenue range mid-point by $8 million reflecting second quarter 2025 results, an updated outlook and average revenue per test trends.”

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1